Lumateperone and Tirzepatide interaction
Lumateperone and Tirzepatide: the Lumateperone prescribing label mentions this combination without an instruction to avoid it or change the dose.
Mentioned, no instruction to avoid. Worth knowing; rarely a reason to change anything on its own.
What the FDA labels say
From the Lumateperone (CAPLYTA) label · effective 2025-06-20
In an uncontrolled open-label trial of CAPLYTA for up to 1 year in adult patients with stable schizophrenia, the percentages of patients with shifts in fasting glucose and insulin values from normal to high were 8% and 12%, respectively.
In data from short-term (6-week), placebo-controlled monotherapy and adjunctive therapy bipolar depression trials, mean changes from baseline and the proportion of patients with shifts from normal to greater than normal levels of fasting glucose and insulin were similar in CAPLYTA-treated and placebo-treated patients.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.